<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: Annual Report ", fill: "#e0b0ff"},
{source: "1: Annual Report ", target: "1: carefully", fill: "#e0b0ff"},
{source: "1: carefully", target: "1: following factors which describe", fill: "#e0b0ff"},
{source: "1: following factors which describe", target: "1: uncertainties", fill: "#e0b0ff"},
{source: "1: uncertainties", target: "1: may materially", fill: "#e0b0ff"},
{source: "1: may materially", target: "1: adversely affect", fill: "#e0b0ff"},
{source: "1: adversely affect", target: "1: products financial condition", fill: "#e0b0ff"},
{source: "1: Annual Report ", target: "5: relying upon", fill: "#c23b22"},
{source: "5: relying upon", target: "5: safe harbor", fill: "#c23b22"},
{source: "5: safe harbor", target: "5: such statements", fill: "#c23b22"},
{source: "5: such statements", target: "5: qualified by reference", fill: "#c23b22"},
{source: "5: qualified by reference", target: "5: cautionary statements set out elsewhere", fill: "#c23b22"},
{source: "5: cautionary statements set out elsewhere", target: "5: Annual Report", fill: "#c23b22"},
{source: "5: relying upon", target: "6: face new competition", fill: "#89cff0"},
{source: "6: face new competition", target: "7: addressing", fill: "#e9d66b"},
{source: "7: addressing", target: "7: competition", fill: "#e9d66b"},
{source: "7: addressing", target: "8: contend successfully with current", fill: "#bd33a4"},
{source: "8: contend successfully with current", target: "8: future competitors", fill: "#bd33a4"},
{source: "8: contend successfully with current", target: "9: pharmaceutical", fill: "#b39eb5"},
{source: "9: pharmaceutical", target: "9: biotechnology industries", fill: "#b39eb5"},
{source: "9: biotechnology industries", target: "9: characterized by rapidly", fill: "#b39eb5"},
{source: "9: characterized by rapidly", target: "9: evolving technology", fill: "#b39eb5"},
{source: "9: evolving technology", target: "9: intense competition", fill: "#b39eb5"},
{source: "9: pharmaceutical", target: "10: competitors", fill: "#f96"},
{source: "10: competitors", target: "10: pharmaceutical", fill: "#f96"},
{source: "10: pharmaceutical", target: "10: biopharmaceutical companies", fill: "#f96"},
{source: "10: biopharmaceutical companies", target: "10: financial technical", fill: "#f96"},
{source: "10: financial technical", target: "10: substantially", fill: "#f96"},
{source: "10: substantially", target: "10: manufacturing", fill: "#f96"},
{source: "10: manufacturing", target: "10: clinical testing", fill: "#f96"},
{source: "10: clinical testing", target: "10: regulatory approvals", fill: "#f96"},
{source: "10: competitors", target: "11: competitors", fill: "#ffd800"},
{source: "11: competitors", target: "11: impact on", fill: "#ffd800"},
{source: "11: impact on", target: "11: revenue from", fill: "#ffd800"},
{source: "11: revenue from", target: "11: products may", fill: "#ffd800"},
{source: "11: competitors", target: "13: Novartis Ophthalmics ", fill: "#18453b"},
{source: "13: Novartis Ophthalmics ", target: "13: North America ", fill: "#18453b"},
{source: "13: North America ", target: "13: competitive", fill: "#18453b"},
{source: "13: Novartis Ophthalmics ", target: "14: competitors", fill: "#00416a"},
{source: "14: competitors", target: "14: proprietary products", fill: "#00416a"},
{source: "14: proprietary products", target: "14: Visudyne ", fill: "#00416a"},
{source: "14: Visudyne ", target: "14: competitive products", fill: "#00416a"},
{source: "14: competitive products", target: "14: approved pending approval", fill: "#00416a"},
{source: "14: approved pending approval", target: "14: development", fill: "#00416a"},
{source: "14: competitors", target: "15: These ", fill: "#c04000"},
{source: "15: These ", target: "15: competitors", fill: "#c04000"},
{source: "15: competitors", target: "15: Genentech and Novartis Ophthalmics Lucentis ", fill: "#c04000"},
{source: "15: Genentech and Novartis Ophthalmics Lucentis ", target: "15: currently pending regulatory approval", fill: "#c04000"},
{source: "15: currently pending regulatory approval", target: "15: cancer but", fill: "#c04000"},
{source: "15: cancer but", target: "15: extensively by physicians", fill: "#c04000"},
{source: "15: extensively by physicians", target: "15: OSI Pharmaceuticals Inc", fill: "#c04000"},
{source: "15: These ", target: "20: approved products on", fill: "#aa98a9"},
{source: "20: approved products on", target: "20: products compete", fill: "#aa98a9"},
{source: "20: approved products on", target: "21: Bayer Pharmaceuticals Corporations Viadur ", fill: "#e0b0ff"},
{source: "21: Bayer Pharmaceuticals Corporations Viadur ", target: "21: Watson Pharmaceuticals Inc", fill: "#e0b0ff"},
{source: "21: Bayer Pharmaceuticals Corporations Viadur ", target: "24: commercialization", fill: "#e7feff"},
{source: "24: commercialization", target: "24: product will", fill: "#e7feff"},
{source: "24: product will", target: "24: directly compete against several", fill: "#e7feff"},
{source: "24: directly compete against several", target: "24: prescription topical products", fill: "#e7feff"},
{source: "24: commercialization", target: "27: face competition on", fill: "#915c83"},
{source: "27: face competition on", target: "27: generic dermatology products", fill: "#915c83"},
{source: "27: generic dermatology products", target: "27: although none", fill: "#915c83"},
{source: "27: although none", target: "27: individually", fill: "#915c83"},
{source: "27: face competition on", target: "29: treatments", fill: "#ff4500"},
{source: "29: treatments", target: "29: future may adversely", fill: "#ff4500"},
{source: "29: future may adversely", target: "29: marketability", fill: "#ff4500"},
{source: "29: treatments", target: "31: BusinessCompetition", fill: "#8a3324"},
{source: "31: BusinessCompetition", target: "36: one lawsuit which", fill: "#0067a5"},
{source: "36: one lawsuit which", target: "36: TAP Pharmaceuticals Inc", fill: "#0067a5"},
{source: "36: one lawsuit which", target: "38: The US TAP ", fill: "#eb4c42"},
{source: "38: The US TAP ", target: "38: litigation began", fill: "#eb4c42"},
{source: "38: litigation began", target: "38: coplaintiffs", fill: "#eb4c42"},
{source: "38: coplaintiffs", target: "38: Atrix Laboratories Inc", fill: "#eb4c42"},
{source: "38: The US TAP ", target: "42: adverse judgment", fill: "#7c0a02"},
{source: "42: adverse judgment", target: "42: Court of Appeals", fill: "#7c0a02"},
{source: "42: adverse judgment", target: "43: agreement", fill: "#adff2f"},
{source: "43: agreement", target: "43: SanofiSynthelabo ", fill: "#adff2f"},
{source: "43: SanofiSynthelabo ", target: "43: commercializes", fill: "#adff2f"},
{source: "43: commercializes", target: "43: US and Canada QLT USA ", fill: "#adff2f"},
{source: "43: US and Canada QLT USA ", target: "43: provided certain", fill: "#adff2f"},
{source: "43: provided certain", target: "43: indemnities", fill: "#adff2f"},
{source: "43: indemnities", target: "43: SanofiSynthelabo ", fill: "#adff2f"},
{source: "43: SanofiSynthelabo ", target: "43: affiliates", fill: "#adff2f"},
{source: "43: affiliates", target: "43: infringement", fill: "#adff2f"},
{source: "43: infringement", target: "43: third partys patent", fill: "#adff2f"},
{source: "43: agreement", target: "44: cannot currently", fill: "#a32638"},
{source: "44: cannot currently", target: "44: potential damages", fill: "#a32638"},
{source: "44: potential damages", target: "44: litigation", fill: "#a32638"},
{source: "44: litigation", target: "44: unsuccessful", fill: "#a32638"},
{source: "44: unsuccessful", target: "44: indemnification", fill: "#a32638"},
{source: "44: indemnification", target: "44: agreement with", fill: "#a32638"},
{source: "44: agreement with", target: "44: SanofiSynthelabo ", fill: "#a32638"},
{source: "44: SanofiSynthelabo ", target: "44: of QLT USA ", fill: "#a32638"},
{source: "44: of QLT USA ", target: "44: consequently", fill: "#a32638"},
{source: "44: cannot currently", target: "49: further details", fill: "#fff"},
{source: "49: further details", target: "49: litigation with", fill: "#fff"},
{source: "49: litigation with", target: "49: TAP Pharmaceuticals Inc", fill: "#fff"},
{source: "49: further details", target: "START_HERE", fill: "#fff"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Accuse</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/You've_Got_to_Be_Carefully_Taught">You've Got to Be Carefully Taught</a></td>
      <td>"You've Got to Be Carefully Taught" (sometimes "You've Got to Be Taught" or "Carefully Taught") is a show tune from the 1949 Rodgers and Hammerstein musical South Pacific.\nSouth Pacific received scrutiny for its commentary regarding relationships between different races and ethnic groups.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Uncertainty_parameter">Uncertainty parameter</a></td>
      <td>The uncertainty parameter U is a parameter introduced by the Minor Planet Center (MPC) to quantify concisely the uncertainty of a perturbed orbital solution for a minor planet. The parameter is a logarithmic scale from 0 to 9 that measures the anticipated longitudinal uncertainty in the minor planet's mean anomaly after 10 years.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cone_of_Uncertainty">Cone of Uncertainty</a></td>
      <td>In project management, the Cone of Uncertainty describes the evolution of the amount of best case uncertainty during a project. At the beginning of a project, comparatively little is known about the product or work results, and so estimates are subject to large uncertainty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cirsium">Cirsium</a></td>
      <td>Cirsium is a genus of perennial and biennial flowering plants in the Asteraceae, one of several genera known commonly as thistles. They are more precisely known as plume thistles.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monopolistic_competition">Monopolistic competition</a></td>
      <td>Monopolistic competition is a type of imperfect competition such that there are many producers competing against each other, but selling products that are differentiated from one another (e.g. by branding or quality) and hence are not perfect substitutes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/IP_address">IP address</a></td>
      <td>An Internet Protocol address (IP address) is a numerical label such as 192.0.2.1 that is connected to a computer network that uses the Internet Protocol for communication. An IP address serves two main functions: network interface identification and location addressing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Seychelles">Seychelles</a></td>
      <td>Seychelles ( (listen), ; French: [sɛʃɛl] or [seʃɛl]), officially the Republic of Seychelles (French: République des Seychelles; Creole: La Repiblik Sesel), is an archipelagic island country consisting of 115 islands in the Indian Ocean at the eastern edge of the Somali Sea. Its capital and largest city, Victoria, is 1,500 kilometres (800 nautical miles) east of mainland Africa.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preclinical_development">Preclinical development</a></td>
      <td>In drug development, preclinical development, also termed preclinical studies or nonclinical studies, is a stage of research that begins before clinical trials (testing in humans) and during which important feasibility, iterative testing and drug safety data are collected, typically in laboratory animals.\nThe main goals of preclinical studies are to determine a starting, safe dose for first-in-human study and assess potential toxicity of the product, which typically include new medical devices, prescription drugs, and diagnostics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_laboratory_scientist">Medical laboratory scientist</a></td>
      <td>A medical laboratory scientist (MLS) or clinical laboratory scientist (CLS) or medical technologist (MT) performs diagnostic testing of blood and body fluids in clinical laboratories. The scope of a medical laboratory scientist's work begins with the receipt of patient or client specimens and terminates with the delivery of test results to physicians and other healthcare providers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_laboratory">Medical laboratory</a></td>
      <td>A medical laboratory or clinical laboratory is a laboratory where tests are carried out on clinical specimens to obtain information about the health of a patient to aid in diagnosis, treatment, and prevention of disease. Clinical Medical laboratories are an example of applied science, as opposed to research laboratories that focus on basic science, such as found in some academic institutions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Swiss_companies_by_revenue">List of Swiss companies by revenue</a></td>
      <td>Switzerland has a large economy and highly skilled labor force. Fifteen Swiss companies are included on Fortune's "Global 500" list (in 2011).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nepafenac">Nepafenac</a></td>
      <td>Nepafenac, sold under the brand name Nevanac among others, is a nonsteroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop 0.1% solution (Nevanac) or 0.3% solution (Ilevro). It is used to treat pain and inflammation associated with cataract surgery.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/British_America">British America</a></td>
      <td>British America comprised the colonial territories of the English Empire, which after the 1707 union of the Kingdom of England with the Kingdom of Scotland to form the Kingdom of Great Britain became the British Empire, in the Americas from 1607 to 1783. Prior to the union, this was termed English America, excepting Scotland's failed attempts to establish its own colonies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitive_advantage">Competitive advantage</a></td>
      <td>In business, a competitive advantage is the attribute that allows an organization to outperform its competitors.\nA competitive advantage may include access to natural resources, such as high-grade ores or a low-cost power source, highly skilled labor, geographic location, high entry barriers, and access to new technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_software">Proprietary software</a></td>
      <td>Proprietary software, also known as non-free software or closed-source software, is computer software for which the software's publisher or another person reserves some licensing rights to use, modify, share modifications, or share the software, restricting user freedom with the software they lease. It is the opposite of open-source or free software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitive_landscape">Competitive landscape</a></td>
      <td>Competitive landscape is a business analysis method that identifies direct or indirect competitors to help comprehend their mission, vision, core values, niche market, strengths, and weaknesses. Based on the volatile nature of the business world, where companies represent a competition to others, this analysis helps to establish a new mind-set which facilitates the creation of strategic competitiveness.Due to the hypercompetition of the environment, the traditional sources of getting competitive advantage does not represent any more an effective strategy, as a result of the emergence of a global economy and technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_I-140">Form I-140</a></td>
      <td>Form I-140, Immigrant Petition for Alien Worker is a form submitted to the United States Citizenship and Immigration Service (USCIS) by a prospective employer to petition an alien to work in the US on a permanent basis. This is done in the case when the worker is deemed extraordinary in some sense or when qualified workers do not exist in the US. The employer who files is called the petitioner, and the alien employee is called the beneficiary; these two can coincide in the case of a self-petitioner.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Approved_Drug_Products_with_Therapeutic_Equivalence_Evaluations">Approved Drug Products with Therapeutic Equivalence Evaluations</a></td>
      <td>Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, is a publication produced by the United States Food and Drug Administration (FDA), as required by the Drug Price and Competition Act (Hatch-Waxman Act).\nThe Hatch-Waxman Act was created to '"strike a balance between two competing policy interests:\n\ninducing pioneering research and development of new drugs and\nenabling competitors to bring low-cost, generic copies of those drugs to market'".The Orange Book identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Oracle_Database">Oracle Database</a></td>
      <td>Oracle Database (commonly referred to as Oracle DBMS, Oracle Autonomous Database, or simply as Oracle) is a multi-model database management system produced and marketed by Oracle Corporation.\nIt is a database commonly used for running online transaction processing (OLTP), data warehousing (DW) and mixed (OLTP &amp; DW) database workloads.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/FTC_v._Actavis,_Inc.">FTC v. Actavis, Inc.</a></td>
      <td>FTC v. Actavis, Inc., 570 U.S. 136 (2013), was a United States Supreme Court decision in which the Court held that the FTC could make an antitrust challenge under the rule of reason against a so-called pay-for-delay agreement, also referred to as a reverse payment patent settlement.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MTV_Roadies_(season_18)">MTV Roadies (season 18)</a></td>
      <td>Roadies Revolution is the seventeenth season of India MTV Roadies, which premiers on MTV on February 15, 2020. Prince Narula, Nikhil Chinapa, Neha Dhupia and Raftaar (Varun Sood replaced him mid season) returned as Leaders while Rannvijay Singh continues as the host.In this season, there is no gang leader nor any gang.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Singles:_Individually_Wrapped">Singles: Individually Wrapped</a></td>
      <td>Singles: Individually Wrapped is a greatest hits album by The Odds, released in 2000. The album contains singles from all four of the band's studio albums, as well as a rendition of the Christmas song "Kings of Orient" which the band recorded for the 1991 Christmas compilation A Lump of Coal.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/National_Register_of_Historic_Places">National Register of Historic Places</a></td>
      <td>The National Register of Historic Places (NRHP) is the United States federal government's official list of districts, sites, buildings, structures and objects deemed worthy of preservation for their historical significance. A property listed in the National Register, or located within a National Register Historic District, may qualify for tax incentives derived from the total value of expenses incurred in preserving the property.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_valuation">Business valuation</a></td>
      <td>Business valuation is a process and a set of procedures used to estimate the economic value of an owner's interest in a business.  Here various valuation techniques are used by financial market participants to determine the price they are willing to pay or receive to effect a sale of the business.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_lawsuits_involving_Donald_Trump">List of lawsuits involving Donald Trump</a></td>
      <td>The following is a list of notable lawsuits involving former United States president Donald Trump. The list excludes cases that name Trump as legal formality in his capacity as president, such as habeas corpus requests.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Microsoft_litigation">Microsoft litigation</a></td>
      <td>Microsoft has been involved in numerous high-profile legal matters that involved litigation over the history of the company, including cases against the United States, the European Union, and competitors.\n\n\n== Governmental ==\nIn its 2008 annual report, Microsoft stated:\nGovernment regulatory actions and court decisions may hinder our ability to provide the benefits of our software to consumers and businesses, thereby reducing the attractiveness of our products and the revenues that come from them.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/National_Indemnity_Company">National Indemnity Company</a></td>
      <td>National Indemnity Company is an insurance company based in Omaha, Nebraska, United States, and founded in 1940 by Jack Dabney Ringwalt. It is a subsidiary of Berkshire Hathaway, which bought the company in 1967.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_equipment_of_the_People's_Liberation_Army_Ground_Force">List of equipment of the People's Liberation Army Ground Force</a></td>
      <td>This is a list of military equipment in service with the People's Liberation Army Ground Force, either presently, or former equipment that has since been replaced.\n\n\n== Individual equipment ==\n\n\n== Small arms and light weapon ==\n\n\n=== Small arms ===\n\n\n=== Grenades, explosives, and missiles ===\n\n\n=== Mortars and recoilless rifles ===\n\n\n=== Other ===\n\n\t\t\n\t\t\n\t\t\n\t\t\n\n\n== Artillery ==\n\n\n=== Gun artillery ===\n\n\n=== Multiple rocket artillery ===\n\n\n=== Anti-aircraft artillery ===\n\n\n=== Other ===\n\n\t\t\n\t\t\n\t\t\n\t\t\n\n\n== Vehicle ==\n\n\n=== Armored combat vehicles ===\n\n\n=== Anti-tank/anti-structure vehicles ===\n\n\n=== Logistic and support vehicles ===\n\n\n=== Other ===\n\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\n\n== Vessel ==\n\n\n== Aircraft ==\n\n\n== Equipment summary (2021) ==\nData estimated by The International Institute for Strategic Studies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>QLT INC/BC      Item 1A RISK FACTORS     In addition to the other information included in this <font color="blue">Annual Report</font>, you     should consider <font color="blue">carefully</font> the following factors, which describe the risks,     <font color="blue">uncertainties</font> and other factors that <font color="blue">may materially</font> and <font color="blue">adversely affect</font> our     business,  products, <font color="blue">financial condition</font> and operating results</td>
    </tr>
    <tr>
      <td>We are     identifying these <font color="blue">as important factors</font> that could cause actual events or our     actual results to <font color="blue">differ materially from</font> those contained in any written or     oral  forward-looking  statements  (within  the meaning of the Private     Securities Reform Act of 1995 and “forward looking information” within the     meaning <font color="blue">of Canadian </font><font color="blue">securities legislation</font>) made by us or on our behalf in     this <font color="blue"><font color="blue">Annual Report</font> </font>or elsewhere</td>
    </tr>
    <tr>
      <td>The <font color="blue">risks described</font> below are not the only     ones that may exist</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks not <font color="blue">currently known by us</font> or that we     consider  immaterial  at the present time <font color="blue">may also impair</font> our business     <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">relying upon</font> the <font color="blue">safe harbor</font> for     forward-looking statements and information and any <font color="blue">such statements</font> are     <font color="blue">qualified by reference</font> to the <font color="blue">cautionary statements set out elsewhere</font> in     this <font color="blue">Annual Report</font></td>
    </tr>
    <tr>
      <td>Risks Relating to Our Business     We <font color="blue">face new <font color="blue">competition</font></font> for Visudyne</td>
    </tr>
    <tr>
      <td>We may not be successful in <font color="blue">addressing</font>     <font color="blue">competition</font> for Visudyne, Eligard or our other products</td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">contend successfully with current</font> or <font color="blue">future <font color="blue">competitors</font></font></td>
    </tr>
    <tr>
      <td>The <font color="blue">pharmaceutical</font> and <font color="blue">biotechnology industries</font> are <font color="blue">characterized by rapidly</font>     <font color="blue">evolving technology</font> and intense <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> include major     <font color="blue">pharmaceutical</font> and bio<font color="blue">pharmaceutical</font> companies, many of which have access to     financial, technical and marketing resources significantly greater than ours     and  <font color="blue">substantially</font>  greater experience in developing and <font color="blue">manufacturing</font>     products,  conducting  preclinical  and <font color="blue">clinical testing</font> and obtaining     <font color="blue">regulatory approvals</font></td>
    </tr>
    <tr>
      <td>We are aware of a number of <font color="blue">competitors</font> and potential     <font color="blue">competitors</font> to our products and the <font color="blue">impact on</font> the sales of our products and     our <font color="blue">revenue from</font> the sales of our <font color="blue">products may</font> be material</td>
    </tr>
    <tr>
      <td>Some of these     <font color="blue">competitors</font> are also our <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>For example, Novartis Ophthalmics,     who has the marketing rights to our product Visudyne, has also acquired     rights to market Lucentis outside of North America, a product that when     approved will be <font color="blue">competitive</font> with Visudyne</td>
    </tr>
    <tr>
      <td>The  following  are examples of <font color="blue">competitors</font> to certain of our approved     <font color="blue">proprietary products</font>:     <font color="blue">Visudyne  </font>Competition  — There are a number of <font color="blue">competitive</font> products to     <font color="blue">Visudyne  </font>that are approved, pending approval or in <font color="blue">development</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">competitors</font> include: Genentech and Novartis Ophthalmic’s Lucentis™ which is     <font color="blue">currently pending regulatory approval</font> in the US and Europe, Genentech’s     Avastin^®  which  is  approved  for <font color="blue">cancer but</font> is being used off-label     <font color="blue">extensively by physicians</font> for the treatment of wet AMD, Eyetech (now part of     OSI Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>) and Pfizer’s Macugen^® which is approved in the     US and Europe for the treatment of all                                         31       _________________________________________________________________           forms  of  wet  AMD,  and Alcon’s Retaane^® which is the subject of an     <font color="blue">approvable letter</font> in the US (which we expect means that Alcon may need to     <font color="blue">conduct further studies prior</font> to obtaining <font color="blue">registration</font> in the US) and is     approved  in  Australia</td>
    </tr>
    <tr>
      <td>are also     developing  or  may develop <font color="blue">competitive</font> therapies targeted for wet AMD     <font color="blue">employing different technologies</font></td>
    </tr>
    <tr>
      <td>We also believe that Visudyne could be     <font color="blue">competing against surgical</font> or other <font color="blue">treatments</font> for AMD, including macular     translocation, submacular surgery and laser photocoagulation, among others</td>
    </tr>
    <tr>
      <td>Eligard Competition — There are a number of <font color="blue">approved products on</font> the market     with  which  our Eligard <font color="blue">products compete</font></td>
    </tr>
    <tr>
      <td>These include AstraZeneca’s     Zoladex^® product, Bayer Pharmaceuticals Corporation’s Viadur^® product,     Watson Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>Aczone  Competition  — Upon <font color="blue">commercialization</font>, our Aczone <font color="blue">product will</font>     <font color="blue">directly compete against several</font> other <font color="blue">prescription topical products</font> for the     treatment   of   acne</td>
    </tr>
    <tr>
      <td>These   include,  but  are  not  limited  to,     erythromycin/benzoyl peroxide, clindamycin/benzoyl peroxide, tretinoin, and     <font color="blue">adapalene</font>  products</td>
    </tr>
    <tr>
      <td>Aczone <font color="blue">will also compete indirectly with systemic</font>     <font color="blue">prescription products</font> and topical over-the-counter therapies</td>
    </tr>
    <tr>
      <td>In addition, we face <font color="blue">competition</font> on all of our <font color="blue">generic dermatology products</font>,     <font color="blue">although none</font> of the <font color="blue">generic dermatology products</font> are <font color="blue">individually</font> material     to our business</td>
    </tr>
    <tr>
      <td>We  are  aware  of other <font color="blue">products <font color="blue">manufacture</font>d</font> or under <font color="blue">development</font> by     <font color="blue">competitors</font>  that are used for the prevention and treatment of certain     diseases that we have targeted for product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The existence of     these products, or other products or <font color="blue">treatments</font> of which we are not aware,     or products or <font color="blue">treatments</font> that may be developed in the future, may adversely     affect the <font color="blue">marketability</font> of our products</td>
    </tr>
    <tr>
      <td>More information on the <font color="blue">competitors</font> and potential <font color="blue">competitors</font> can be found     under Item 1</td>
    </tr>
    <tr>
      <td>Business-Competition</td>
    </tr>
    <tr>
      <td>If there is an <font color="blue">adverse outcome</font> in the <font color="blue">ongoing patent <font color="blue">litigation</font> with</font> TAP     Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>or any other <font color="blue">litigation</font> or other <font color="blue">legal actions</font> in     which we are or may become involved our business may be harmed</td>
    </tr>
    <tr>
      <td>We and certain of our <font color="blue">subsidiaries</font> are or may become involved in various     types of <font color="blue">litigation</font> that arise from time to time in the <font color="blue">ordinary course</font> of     our business</td>
    </tr>
    <tr>
      <td>We are currently a <font color="blue">defendant</font> in <font color="blue">four lawsuits filed against</font>     us</td>
    </tr>
    <tr>
      <td>In <font color="blue">one lawsuit which</font> was commenced in the US by TAP Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>and its co-plantiffs, we <font color="blue">recently lost</font> the <font color="blue">trial court decision</font> and intend     to appeal this decision</td>
    </tr>
    <tr>
      <td><font color="blue">The US TAP </font><font color="blue">litigation</font> began in 2003 when TAP and     its co-plaintiffs sued Atrix Laboratories, Inc</td>
    </tr>
    <tr>
      <td>(now our subsidiary, QLT     USA) and Sanofi-Synthelabo alleging that QLT USA’s Eligard <font color="blue">product infringes</font>     their ‘721 patent, which expires on May 1, 2006</td>
    </tr>
    <tr>
      <td><font color="blue">In the TAP </font><font color="blue">litigation</font>, a     jury upheld the validity of the ‘721 patent and the <font color="blue">US District Court </font>for     the  <font color="blue">Northern District of Illinois Eastern Division </font>denied <font color="blue">defendant</font>s’     defense that the ‘721 patent is <font color="blue">unenforceable due</font> to <font color="blue">inequitable conduct by</font>     the patentees before the <font color="blue">US Patent and Trademark Office</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">discovery</font> and     pre-trial phase for the damages portion of the trial is scheduled to begin     in 2006</td>
    </tr>
    <tr>
      <td>QLT USA and Sanofi-Synthelabo intend to appeal the <font color="blue">adverse judgment</font>     to the <font color="blue">Court of Appeals</font></td>
    </tr>
    <tr>
      <td>Under the marketing <font color="blue">agreement</font> entered into between     QLT USA and Sanofi-Synthelabo under which Sanofi-Synthelabo <font color="blue">commercializes</font>     our Eligard products in the US and Canada, QLT USA has <font color="blue">provided certain</font>     <font color="blue">indemnities</font> to Sanofi-Synthelabo and its <font color="blue">affiliates</font>, including <font color="blue">indemnities</font>     covering certain losses relating to <font color="blue">infringement</font> of a third party’s patent     rights</td>
    </tr>
    <tr>
      <td>While we <font color="blue">cannot currently</font> estimate the <font color="blue">potential damages</font> in the TAP     <font color="blue">litigation</font> in the event that QLT USA is <font color="blue">unsuccessful</font> in its appeal, or what     level of <font color="blue">indemnification</font>, if any, will be required under the marketing     <font color="blue">agreement</font> with Sanofi-Synthelabo, the amount could be substantial, which     could have a material adverse <font color="blue">impact on</font> the <font color="blue">financial condition</font> <font color="blue">of QLT USA     </font>and <font color="blue">consequently</font>, on QLT Inc</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>is inherently unpredictable, and <font color="blue">excessive verdicts</font> do occur     which may include a judgment with significant monetary award, including the     <font color="blue">possibility</font> of <font color="blue">punitive damages</font>, a judgment that certain of our patent or     other <font color="blue">intellectual property rights</font> are invalid or unenforceable and, as has     occurred in the US <font color="blue">litigation</font> with TAP Pharmaceuticals, the risk that an     injunction could be issued preventing the <font color="blue">manufacture</font>, marketing and sale of     our products that are the subject of the <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Furthermore, we will     have to incur substantial expense in defending these lawsuits and the time     demands of these lawsuits could divert management’s attention from ongoing     business concerns and <font color="blue">interfere with</font> our normal <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Although we     believe we have substantial defenses in these matters, we could in the     <font color="blue">future incur judgments</font> or <font color="blue">enter into settlements</font> of claims that could have a     material adverse effect on our <font color="blue">financial condition</font> and results of <font color="blue">operations</font>     in any <font color="blue">particular period</font></td>
    </tr>
    <tr>
      <td>For <font color="blue">further details</font> of the                                         32       _________________________________________________________________           <font color="blue">litigation</font> with TAP Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>and its co-plaintiffs and the     <font color="blue">current status</font> of our other intellectual property <font color="blue">litigation</font>, please refer</td>
    </tr>
  </tbody>
</table>